Sanofi

Sanofi Tangible Book Value per Share

The Tangible Book Value per Share of Sanofi (SAN.PA) as of Nov 3, 2026 is -30.72 EUR. In the previous year, Tangible Book Value per Share was 9.42 EUR — a change of -426.13% (lower).

Tangible Book Value per Share

-30.72EUR

YoY

-426.13%

Last updated:

Tangible Book Value per Share of Sanofi is 2025 -30.72 EUR. Tangible Book Value per Share of Sanofi was 2024 9.42 EUR. It decreases by -426.13% lower compared to the previous year.

The Sanofi Tangible Book Value per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Tangible Book Value per Share
Date
Tangible Book Value per Share
Jan 1, 2018
-5.94 EUR
Jan 1, 2019
-1.72 EUR
Jan 1, 2020
0.24 EUR
Jan 1, 2021
-0.64 EUR
Jan 1, 2022
1.32 EUR
Jan 1, 2023
0.26 EUR
Jan 1, 2024
9.42 EUR
Jan 1, 2025
-30.72 EUR
The Sanofi Tangible Book Value per Share history
YEARTangible Book Value per ShareYoY
-30.72EUR-426.13%
9.42EUR+3,525.87%
0.26EUR-80.33%
1.32EUR-306.14%
-0.64EUR-364.19%
0.24EUR-114.14%
-1.72EUR-71.11%
-5.94EUR-253.36%
3.87EUR-26.02%
5.23EUR-1.21%
5.30EUR+171.68%
1.95EUR-41.13%
3.31EUR-569.81%
-0.71EUR-84.49%
-4.55EUR-168.30%
6.66EUR+79.95%
3.70EUR+234.66%
1.11EUR-179.83%
-1.38EUR-71.71%
-4.89EUR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Sanofi Stock analysis

What does Sanofi do? Sanofi SA is a French company that was formed in 1973 from a merger of two French pharmaceutical and biotechnology companies. It is one of the largest players in the healthcare industry worldwide and employs over 100,000 employees. The objective of Sanofi is to improve people's lives through innovative medicines and therapies. In this regard, the company pursues a comprehensive business model that focuses on both research and development, as well as the production and distribution of medications and vaccines. The company has different divisions and product lines, which are divided into three business areas: Innovative Medicine, Consumer Healthcare, and Generic Pharmaceuticals. Innovative Medicine utilizes state-of-the-art technologies and scientific knowledge to treat the most challenging diseases. In the area of Consumer Healthcare, the company offers a wide range of over-the-counter products such as vitamins, dietary supplements, cough and cold remedies, as well as oral and dental health products. In the Generic Pharmaceuticals field, the company produces more cost-effective alternatives to expensive brand-name products, providing a variety of generic medications. Sanofi is a leading manufacturer of medications that are of great significance in various areas such as diabetes, oncology, cardiovascular diseases, and neurology. In recent years, the company has also established a strong presence in the field of vaccines. Here, Sanofi develops and produces innovative vaccines against COVID-19, influenza, and other infectious diseases. Sanofi is present in more than 170 countries and collaborates closely with physicians, research institutions, and health authorities to improve healthcare worldwide. The company conducts research and development in various disciplines and invests a significant amount each year in the development of innovative medicines and therapies. Overall, Sanofi SA is an emerging company in the pharmaceutical and healthcare sector. The portfolio of products and therapies offered by Sanofi is extensive and covers many areas of healthcare. Sanofi relies on continuous innovation and continuously works to improve healthcare and enhance the lives of people worldwide. Sanofi is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Sanofi stock

Tangible Book Value per Share of Sanofi is -30.72 EUR in 2025.

Tangible Book Value per Share of Sanofi changed from 9.42 EUR to -30.72 EUR, representing a -426.13% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Tangible Book Value per Share Sanofi since 2006 – with annual values, charts, and detailed analysis.

Tangible book value per share excludes intangible assets and goodwill, providing a more conservative measure of per-share net asset value.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Sanofi

All Key Metrics — Sanofi